The present invention relates to the field of transcatheter stent-valves. In some non-limiting aspects, the stent-valve may be a cardiac valve, for example, an aortic valve.
Transcatheter valve implantation (for example, transcateter aortic valve implantation (TAVI)) is an evolving technology for replacement valve therapy that (i) avoids the trauma of conventional open-chest surgery, and (ii) avoids the need for heart and lung bypass. In such a technique, a stent-valve is compressed and loaded into a delivery catheter. The delivery catheter is introduced to the desired site of implantation (for example at the heart) via a percutaneous route or via minimally invasive surgery. The stent-valve is deployed into the implantation position from or by the delivery catheter, and the delivery catheter is then withdrawn.
Despite the successes of transcatheter stent-valves, technological challenges remain. One such challenge is preventing leakage of blood around the stent-valve (so called para-valve leakage). The above stents form a friction fit with the native anatomy to anchor the stent-valve in position, and are round in cross-section. However the native anatomy in which the stent is implanted is often off-round and is different for each person. Moreover, heavy calcification of the native anatomy may obstruct full deployment of any stent, and make the native anatomy even more irregular. It can sometimes be difficult to provide a perfectly sealing fit between the stent-valve and the surrounding anatomy.
In order to address para-valve leakage, it is known to incorporate an external skirt or cover as part of the stent-valve. For example, the skirt is made of compressible biocompatible material, such as paracardial tissue or PET. The thicker the material of the skirt, the more able the skirt is to occlude gaps and effect a seal. However, a disadvantage is that such skirts add to the bulk of the stent-valve. A thick skirt makes the stent-valve problematic to compress to a desirably small size for implantation.
It would be desirable to provide a technique for mitigating para-valve leakage without substantially hindering the compressibility of a stent-valve.
Aspects of the invention are defined in the claims.
Additionally or alternatively, one aspect of the present invention provides a stent-valve for transcatheter delivery, the stent-valve comprising a stent supporting a plurality of valve leaflets.
Various embodiments present a seal for mitigating para-valve leakage (which may also be referred to herein throughout as a seal or a para(-)valvular seal or a para(-)valvular leakage seal). The seal may be of flexible and/or compliant material. For example, flexible and/or compliant material may comprise natural tissue (e.g. pericardium, such as porcine pericardium or bovine pericardium), and/or synthetic material (e.g. silicone, PET or PEEK, any of which may be in film form, or woven fabric form, or non-woven fabric/mesh form).
In some embodiments, the paravalve seal may be configured to be a substantially supra-annular seal (for example, above the level of a native annulus of the native valve), and/or a substantially annular seal (for example, at the level a native annulus of the native valve), and/or a substantially infra-annular seal (for example, below the level of a native annulus of the native valve).
In some embodiments, a seal is carried by at least one seal support. Additionally or alternatively, a (e.g. deployable) seal support is provided for deploying a seal.
In either case, in some embodiments, the seal support is collapsible to a stowed condition in which the seal is relatively streamlined or compressed with respect to the stent, or to at least a further portion of the stent, when the stent is compressed. (For example, in the stowed condition, the seal support may be generally coplanar with a portion, such as a body portion, of the stent, or may be arranged compressed against the stent or stent portion.) The seal support may be deployable to a deployed condition in which the support holds or biases the seal to a deployed state, for example, with respect to the stent or at least the further portion of the stent previously referred to. The seal support may be self-deploying from the stowed condition to the deployed condition. For example, the seal support may be constrainable in the stowed condition by sheathing of the stent in a compressed state for delivery. The seal support may be self-deploying from the stowed condition when the effect of the constraining sheath is removed. The seal support may be of shape memory material, for example, shape memory metal alloy, for example nitinol.
Various forms and structure of seal support are envisaged. In some embodiments, the seal support, may be integral with the stent (e.g. integrally formed as part of the stent). In other forms, the seal support may be distinct from the stent. Such a seal support may optionally be coupled to or captive on the stent.
The seal support may be configured to bear against the material of the seal without penetrating through the seal material. For example, the seal support may have a shape that distributes contact force. A function of the seal support may be to urge the seal outwardly without the seal support penetrating through the seal material or into a tissue surface against which the seal is desired.
In some embodiments, the seal support comprises a biasing element that biases the seal, for example, to a deployed condition. The seal support (e.g. biasing element) may comprise, for example, a cantilever element (or a plurality of cantilever elements). Each cantilever element may comprise a single strut, or plural struts (for example, first and second struts coupled together at an apex or a tip of the cantilever element). The cantilever elements may be capable of flexing independently of one another, in order to provide a high degree of local seal conformity against an irregular lumen or tissue surface. In some embodiments, each cantilever element is associated with a respective aperture of a lattice structure of the stent. The cantilever elements may, for example, have one end coupled (or integral) with the stent body, and an opposite or remote end that is free to deploy outwardly. The remote end may have a rounded or enlarged or pad tip to avoid having a sharp end that might otherwise risk penetrating through the seal material. The cantilever elements may extend generally in the same direction as each other (e.g. having the remote end directed to one end (such as the outflow end) of the stent-valve), or the cantilever elements may be arranged in two opposite directions (e.g. at least one pointing towards the outflow end, and at least another pointing towards the inflow end), or the cantilever elements may be arranged in a variety of different directions.
In some embodiments, the seal support comprises a ring shape, or tubular shape, or annular member. The member may have an annular coil shape.
In some embodiments, the seal support comprises a member that can be stowed in a generally elongate or helical form, and which deploys to a radially expanded loop form.
In some embodiments, the seal support comprises a portion of the stent that everts from a stowed condition to a deployed condition. Eversion of the stent can provide radial expansion upon deployment without increasing significantly the diameter of the stent when compressed (de-everted). For example, an inflow end or portion of the stent may evert towards the outflow end.
In some embodiments, the stent carries a sealing skirt (or web). The seal support may bias biasing the skirt (or portions thereof) radially outwardly to distend away from the body of the stent.
Additionally or alternatively to the above aspect of the provision of a seal support, a seal of the stent-valve may be configured to be responsive to direction of blood flow past the seal, relative to inflow and outflow ends of the stent-valve. The seal may be configured such that blood flow in a reverse direction (for outflow to inflow) biases the seal to a deployed state to obstruct such flow.
For example, the seal may comprise at least one web defining one or more pockets. The one or more pockets may be configured to fill with blood in response to blood flow in the reverse direction, such that the pocket distends outwardly. Distention of the pocket can fill a gap between the stent-valve and the surrounding anatomy, to obstruct the reverse flow of blood past the pocket.
In some embodiments, the pocket may be defined or carried at a respective aperture of a lattice structure of the stent. The pocket may be defined at least partly by an outer skirt carried on an exterior of the stent. Additionally or alternatively, the pocket may be defined at least partly by an inner skirt carried on an interior of the stent.
Additionally or alternatively to the above aspects, a seal may comprise a skirt at least a portion of which is captive with respect to the stent, and at least a further portion of which is free to deploy or float relative to the stent.
In some embodiments, the further portion may contact a surrounding tissue or lumen wall before the body of the stent is fully deployed. As part of the deployment procedure, the stent may be displaced or biased in a first axial direction to seat against native leaflets. The frictional contact of the skirt against the tissue may cause the further portion of the skirt to bunch or wrinkle in the axial direction during the displacement action. Such bunching or wrinkling may provide additional material to fill voids or gaps between the stent and the surrounding tissue.
Additionally or alternatively, in some embodiments, the further portion of the skirt may be responsive to direction or paravalve blood flow or to pressure of blood acting on the skirt (for example, on the further portion of the skirt). The further portion may, for example, deploy outwardly to contact a surrounding tissue lumen wall. The further portion may form a flap, or generally channel or annular pocket shape in response to, and/or that is responsive to, pressure of blood or flow of blood in the reverse direction. The flap/channel/pocket shape may bias an outer portion of the skirt to seat against the surrounding tissue or lumen surface.
Additionally or alternatively to the above aspects, a seal of the stent-valve may be embossed to present a non-smooth surface. For example, the embossing may be defined by one or more sutures. The one or more sutures may define a zig-zag pattern. The suture may define a generally continuous embossment to obstruct blood flow therepast.
Additionally or alternatively to the above aspects, a seal of the stent-valve may be generally oversized compared to the diameter of the stent. The seal may be bunched or pleated by connections (e.g. suturing) to the stent that causes bunching or pleating between the connections. The bunching/pleating may create additional compliant bulk of seal material able to fill voids or gaps between the stent-valve and the surrounding tissue or lumen surface. The positions of the connections may define bunching or pleating in directions in a pattern that obstructs leakage of blood therepast.
Additionally or alternatively to the above aspects, a seal of the stent-valve may be configured to be self-expanding or self-filling due to a physical property of the seal.
For example, in some embodiments, the seal may be of or comprise a swellable material, foam, sponge or fibrous material. Such a material may self-expand resiliently when the stent deploys. Additionally or alternatively, such a material may absorb blood (and/or a blood component) within its pores or interstices in order to expand the material physically or add bulk.
In some embodiments, the seal may be generally flat and/or tubular in a stowed state and/or may roll or curl into an annular bead or doughnut when in a deployed state. The seal may be self-biased to the deployed state, but be resiliently deformable to the stowed state during compression of the stent for loading into a delivery apparatus. Upon removal of a constraining effect of a sheath of the delivery apparatus, the seal may be configured to readopt the deployed state, in order to provide a radially enlarged seal around the stent.
In some embodiments, at least a portion of the stent comprises a lattice structure, and the stent-valve further comprises one or more seals deployable from or through apertures of the lattice. In one form, the seals comprise web portions of material that define pockets associated with respective apertures of the lattice. The web portions may be configured to distend outwardly from the respective apertures. For example, in some embodiments, the web portions define pockets open on or to one side such that a respective pocket fills with blood to distend outwardly from the aperture of the lattice. Additionally or alternatively, the lattice structure of the stent may comprise biasing elements for biasing the web portions (e.g. pockets) of material radially outwardly from the lattice structure.
In some embodiments, the stent carries a sealing skirt (or web). The stent may comprise biasing elements for biasing the skirt (or portions thereof) radially outwardly to distend away from the body of the stent. The sealing skirt may optionally be carried on the exterior of the stent. An inner skirt (or web) may optionally be carried on the interior of the stent (and optionally coupled directly to the leaflets). At least one of the skirts may be of fabric (e.g. PET). Additionally or alternatively, at least one of the skirts may be of biological tissue, for example, pericardium.
In some embodiments, a biasing element distinct from the stent may bias a seal outwardly. For example, the biasing element may be a ring element (e.g. closed ring or split ring), within an annular seal. The biasing element may be compressible with the stent to a radially compressed condition. The biasing element may expand (e.g. self-expand) towards a radially expanded state when the stent is deployed. The biasing element may be of shape memory material, e.g. nitinol.
Certain features, ideas and advantages of aspects of the invention are identified above and/or in the appended claims, but these do not limit the invention. Protection is claimed for any novel idea or feature described herein and/or illustrated in the drawings whether to not emphasis has been placed thereon.
Non-limiting embodiments of the invention are illustrated in the accompanying drawings, in which:
Referring to
The stent-valve 10 may optionally comprise biological tissue (for example, pericardium (such as porcine pericardium and/or bovine pericardium) and/or natural cardiac valve leaflets (for example, natural porcine cardiac valve leaflets, optionally attached to a portion of natural cardiac wall tissue). The biological tissue may be fixed, for example, using glutaraldehyde. The biological tissue may have anti-calcification properties, for example, having been treated or processed to inhibit or slow calcification (for example, by treatment in alcohol or a process using detergent).
The stent-valve 10 may be compressible to a radially compressed condition (not shown) for delivery using a delivery catheter, and be expandable to an expanded condition (as shown) at implantation. The stent-valve 10 may comprise a stent 12 carrying a plurality of leaflets defining a valve 14. Various geometries of stent 12 may be used. In some embodiments, the stent 12 may include one of more of: a lower tubular or crown portion 16; an upper crown portion 18; a plurality of upstanding commissural supports 20; and a plurality of stabilization arches 22. In use, the lower portion 16 of the stent 12 may be configured to be deployed after the other regions of the stent 12 have first been at least partly deployed. For example, the arches 22, the supports 20 and the upper crown 18 may be deployed at least partly before the lower portion 16 (in that order, or in reverse order, or in a different order). At least once the upper crown 18 has been at least partly deployed, the stent 12 may be urged and/or displaced in the direction of arrow 24 to seat the upper crown 18 against native leaflets at the implantation site. Deploying the lower portion 16 last fixes the stent 12 in its final position.
In some embodiments, at least the lower portion 16, and optionally a portion of the upper crown 18, may be formed by a lattice structure of the stent. The lattice structure may define apertures, for example, generally diamond-shaped apertures.
In some embodiments, the upper crown 18 may be regarded as (e.g., being or comprising) a seal support, when a seal is attached to the upper crown 18. The seal support defined by the upper crown may be considered to deploy the seal at least somewhat outwardly relative to a portion or remainder of the stent just below the upper crown.
The native leaflets may generally overlap a portion 26 of the stent. The native valve annulus may overlap a portion 28 of the stent.
Optionally, the stent-valve 10 may further comprise an inner skirt 30 communicating with the leaflets 14 and carried on an interior of the stent 12. Additionally or alternatively, the stent-valve 10 may further comprise an outer skirt 32 carried on an exterior of the stent 12. When both skirts are provided, the skirts may partially overlap. The skirts may be offset such that one skirt (e.g. the outer skirt 32) extends further towards a lower extremity of the stent 12 than the other (e.g. inner skirt 30). Additionally or alternatively, one skirt (e.g. the inner skirt 30) extends further towards an upper extremity of the stent 12 than the other (e.g. outer skirt 32). The skirts may be of any suitable flexible and/or compliant material, for example, fabric (e.g. of PET), or of plastics film (e.g of PET), or of biological tissue (e.g. of pericardium).
Optionally, at least the outer skirt 32 is positioned to leave (e.g. at least a portion of) the upper crown 18 substantially unobscured by the outer skirt 32. Such an arrangement may assist good blood flow to the coronary arteries (for example, in the case of a stent-valve for the aortic valve).
In some embodiments, the lower portion 16 has an extremity formed with a substantially zig-zag shape. The zig-zag shape may comprise lower apexes 16a and upper apexes 16b. The upper apexes 16b may be masked in
The valve 14 may comprise biological tissue, for example, pericardium (such as porcine pericardium or bovine pericardium) or natural cardiac valve leaflets (for example, natural porcine cardiac valve leaflets, optionally attached to a portion of natural cardiac wall tissue). Other biological or non-biological material could also be used for the valve 14, as desired.
The stent 12 may optionally be of a self-expanding type that is compressible to the compressed state for loading into a delivery catheter having a sheath for constraining the stent 12 in the compressed state for delivery to the site of implantation. In use, by removal of the constraining effect of the sheath, the stent 12 self-expands to or (e.g. at least partly) towards the expanded state. A self-expanding stent may, for example, be of shape-memory material, for example, shape-memory metal alloy, for example, nitinol. Additionally or alternatively, the stent 12 may be configured to be expanded by application of an expanding force from the delivery catheter, such as by using an expansion balloon.
There now follows a description of various seal configurations that may be used with the above-described stent-valve 10. The seal configurations may also be used with different stent shapes and configurations. Whether or not described in detail, the following descriptions of seals may use any single or multiple combination of, aforementioned stent and/or stent-valve features.
Suitable materials for a seal may include biological tissue (for example, pericardium, such as porcine pericardium or bovine pericardium). Biological tissue may be fixed tissue, for example, processed using glutaraldehyde. Pericardium is useful because of its very good flexibility, allowing the seal to conform to fit against and around the irregular shape of hard calcifications. Additionally or alternatively, suitable material for a seal may include plastics (for example, PET or PEEK). Plastics may be used in woven or non-woven fabric form, and/or in sheet form and/or film form, as desired. Plastics may combine toughness with suitable flexibility and conformability. The plastics may be of a biocompatible type.
The cantilever elements 40 may be arranged generally in the same orientation (e.g. with the remote ends 40a directed towards one end, e.g. the outlet end, of the stent 12), or distributed to be orientated in two opposite directions, or be distributed to be orientated in a variety of different directions.
The seal urged by the cantilever elements 40 may be generally continuous, or it may be discontinuous in the form of webs or pockets. The pockets may be arranged such that back-pressure of blood, or para-valvular blood flow in the reverse direction from outlet to inlet end of the stent 12, fills the pockets to cause the pockets further to distend, thereby enhancing the seal effect to obstruct such para-valvular flow. Further detail of such pockets is also described with reference to
Referring to
Referring to
Referring to
As illustrated in
The seal of
As already explained with respect to
The second portion 162 of the skirt 150 may define a pocket or flap that is able to distend outwardly under backpressure or backflow of blood. The flap or pocket may extend continuously over an angle of at least about 180 degrees, optionally at least about 270 degrees, optionally about 360 (e.g. correspond to entirely around the circumferential periphery). The flap or pocket may be substantially annular and/or channel shaped.
In use, when the stent-valve is in its implanted position, the second portion 162 of the skirt may distend against surrounding tissue, for example, under backpressure of blood acting on the stent-valve 10 when the valve 14 has closed, or para-valve leakage of blood backflowing around the stent-valve 10. Distention of the second skirt portion 162 may define a pocket, such that the backpressure of blood within the pocket effects a seal against the surrounding tissue. In some aspects, the second skirt portion 162 may function similarly to the skirt 90 of
The skirt 150 may be dimensioned such that the end 154 closest to the outlet may be positioned axially at a desired position. For example, in
At least in the examples of
In all examples, the end 154 may have a substantially straight edge, or it may have a non-straight edge, for example, an undulating shape, or castellated shape, or notched shape. The variations in a non-straight edge may optionally align with apexes of the upper crown 18. Providing a non-straight edge may, in some embodiments, enable a reduction in the bulk of material of the skirt 150 to be compressed for loading on to or in to a delivery apparatus, which may be significant when the skirt 150 overlaps a region of the stent-valve 10 that is “crowded” in terms of stent material and/or leaflet material and/or skirt material to be compressed.
In some embodiments, the second skirt portion 162 may be wholly unattached to the stent 12. Alternatively, in some embodiments, one or more control attachments 166 may be formed between the second skirt portion 162 and the stent 12 (for example, the upper crown 18). The control attachments 166 may be configured to permit the second skirt portion 162 to distend substantially freely, while preventing unwanted everting of the second skirt portion 162 (e.g. during compression and loading the stent-valve by an inexperienced user).
The upper crown 18 may act as a seal support. For example, the attachment positions 168 may directly support the second skirt portion 162. Additionally or alternatively, when the upper crown 18 is deployed, the upper crown 18 may at least partly bias the second skirt portion 162 outwardly, for example with respect to the waist between the upper crown 18 and the lower portion 16. Such biasing may urge the second skirt portion 162 (i) into engagement with surrounding tissue and/or (ii) to a distended shape defining a flap or pocket responsive to blood back-pressure and/or blood back-flow around the exterior of the stent-valve 10. The upper crown 18 (and seal support) may comprise cantilever elements. The cantilever elements may be flexible independently of one another. Each cantilever element may have a U-shape or V-shape. Each cantilever element may comprise a pair of struts that meet at the apex of the cantilever element.
Attachment of the end 154 to the upper crown may provide additional control over the otherwise free second skirt portion 162. Such an arrangement may facilitate, for example, compressing and loading of the stent-valve 10 for implantation, and avoid risk of the second skirt portion 162 being accidentally everted.
The attachment positions 168 between the end 154 of the skirt 150 and the upper crown 18 may be chosen and/or varied as desired. In the embodiment of
The skirt 150 may have any desired profile shape. For example, in some embodiments, the skirt 150 may have a substantially cylindrical shape. The diameter of the cylindrical shape may correspond to the maximum diameter of the lower portion 16 and/or to the diameter of the stent 12 (e.g. upper crown 18) at the point reached by the end 154 of the skirt 150, and/or the maximum diameter of the upper crown 18, and/or a dimension larger than the upper crown. The waist defined between the upper crown 18 and the lower portion 16, and/or the oversizing of a stent 12 with respect to the size of the native valve to be replaced (typically about 1, 2 or 3 mm diameter oversizing), may provide an excess of skirt material able to distend or billow outwardly for the sealing effect. Additionally or alternatively, the skirt 150 may be sculpted with a non-cylindrical shape, for example, a bulbous shape or a funnel shape, also to provide excess material able to distend or billow outwardly for the sealing effect.
As already described, the seals and/or skirts of any of the forgoing embodiments may be made of any suitable material. Suitable material may include biological tissue (for example, pericardium (for example, porcine pericardium or bovine pericardium). Additionally or alternatively, suitable material may include plastics (for example, PET or PEEK). Plastics may be used in woven or non-woven fabric form, and/or in sheet form, and/or in film form.
Although the seal arrangements have been described as alternatives, it is envisaged that any two or more of the seal arrangements may be combined for synergistic effect. It will also be appreciated that the foregoing description is merely illustrative of example forms of the invention and that many modifications and alternatives may be used within the scope of the invention.
Any and all references to publications or other documents, including but not limited to, patents, patent applications, articles, webpages, books, etc., presented in the present application, are herein incorporated by reference in their entirety.
Example embodiments of the devices, systems and methods have been described herein. As noted elsewhere, these embodiments have been described for illustrative purposes only and are not limiting. Other embodiments are possible and are covered by the disclosure, which will be apparent from the teachings contained herein. Thus, the breadth and scope of the disclosure should not be limited by any of the above-described embodiments but should be defined only in accordance with claims supported by the presented disclosure and their equivalents. Moreover, embodiments of the subject disclosure may include methods, systems and devices which may further include any and all elements from any other disclosed methods, systems and devices including any and all elements corresponding to stent-valves and/or seals for stent-valves. In other words, elements from one or another disclosed embodiments may be interchangeable with elements from other disclosed embodiments. In addition, one or more features of disclosed embodiments may be removed and still result in patentable subject matter (and this, resulting in yet more embodiments of the subject disclosure).
Number | Date | Country | Kind |
---|---|---|---|
12002015 | Mar 2012 | EP | regional |
This application is a continuation of U.S. application Ser. No. 14/777,503 filed Sep. 15, 2015 which is a national stage application of and claims priority to International Patent Application No. PCT/EP2013/000893, filed Mar. 25, 2013, and entitled “Improvements Relating to Transcatheter Stent-Valves.” This application also claims priority to U.S. patent application Ser. No. 13/839,357, filed Mar. 15, 2013, entitled “Transcatheter Stent-Valves and Methods, Systems and Devices for Addressing Para-Valve Leakage,” as well as European patent application no. 12002015.1, filed Mar. 22, 2012. The present application incorporates herein by reference the disclosures of each of the above-referenced applications in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3755823 | Hancock | Sep 1973 | A |
4106129 | Carpentier et al. | Aug 1978 | A |
4470157 | Love | Sep 1984 | A |
5078720 | Burton et al. | Jan 1992 | A |
5163955 | Love et al. | Nov 1992 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5344442 | Deac | Sep 1994 | A |
5354330 | Hanson et al. | Oct 1994 | A |
5411552 | Andersen et al. | May 1995 | A |
5480424 | Cox | Jan 1996 | A |
5499995 | Teirstein | Mar 1996 | A |
5500015 | Deac | Mar 1996 | A |
5540712 | Kleshinski et al. | Jul 1996 | A |
5571174 | Love et al. | Nov 1996 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5653749 | Love et al. | Aug 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5713950 | Cox | Feb 1998 | A |
5713951 | Garrison et al. | Feb 1998 | A |
5718725 | Sterman et al. | Feb 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5807327 | Green et al. | Sep 1998 | A |
5817126 | Imran | Oct 1998 | A |
5823956 | Roth et al. | Oct 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855600 | Alt | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5861028 | Angell | Jan 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6102944 | Huynh et al. | Aug 2000 | A |
6110201 | Quijano et al. | Aug 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6183481 | Lee et al. | Feb 2001 | B1 |
6196230 | Hall et al. | Mar 2001 | B1 |
6214036 | Letendre et al. | Apr 2001 | B1 |
6254564 | Wilk et al. | Jul 2001 | B1 |
6287334 | Moll et al. | Sep 2001 | B1 |
6287339 | Vazquez et al. | Sep 2001 | B1 |
6331189 | Wolinsky et al. | Dec 2001 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6379383 | Palmaz et al. | Apr 2002 | B1 |
6401720 | Tu et al. | Jun 2002 | B1 |
6406493 | Tu et al. | Jun 2002 | B1 |
6409759 | Peredo | Jun 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6530952 | Vesely | Mar 2003 | B2 |
6533807 | Wolinsky et al. | Mar 2003 | B2 |
6537310 | Palmaz et al. | Mar 2003 | B1 |
6562069 | Cai et al. | May 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6572652 | Shaknovich | Jun 2003 | B2 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6589279 | Anderson et al. | Jul 2003 | B1 |
6613079 | Wolinsky et al. | Sep 2003 | B1 |
6635085 | Caffey et al. | Oct 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6682558 | Tu et al. | Jan 2004 | B2 |
6682559 | Myers et al. | Jan 2004 | B2 |
6695865 | Boyle et al. | Feb 2004 | B2 |
6719787 | Cox | Apr 2004 | B2 |
6729356 | Baker et al. | May 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6736827 | McAndrew et al. | May 2004 | B1 |
6755855 | Yurek et al. | Jun 2004 | B2 |
6767362 | Schreck | Jul 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6805711 | Quijano et al. | Oct 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6830585 | Artof et al. | Dec 2004 | B1 |
6830586 | Quijano et al. | Dec 2004 | B2 |
6849085 | Marton | Feb 2005 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6936066 | Palmaz et al. | Aug 2005 | B2 |
6942682 | Vrba et al. | Sep 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025773 | Gittings et al. | Apr 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7041132 | Quijano et al. | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7141064 | Scott et al. | Nov 2006 | B2 |
7149290 | Bennett, III et al. | Dec 2006 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7217287 | Wilson et al. | May 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7285130 | Austin | Oct 2007 | B2 |
7316712 | Peredo | Jan 2008 | B2 |
7318278 | Zhang et al. | Jan 2008 | B2 |
7320704 | Lashinski et al. | Jan 2008 | B2 |
7320705 | Quintessenza | Jan 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7331991 | Kheradvar et al. | Feb 2008 | B2 |
7331993 | White | Feb 2008 | B2 |
7338484 | Schoon et al. | Mar 2008 | B2 |
7361189 | Case et al. | Apr 2008 | B2 |
7371258 | Woo et al. | May 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7377938 | Sarac et al. | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7393358 | Malewicz | Jul 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7399315 | Iobbi | Jul 2008 | B2 |
7402171 | Osborne et al. | Jul 2008 | B2 |
7410499 | Bicer | Aug 2008 | B2 |
7416530 | Turner et al. | Aug 2008 | B2 |
7422603 | Lane | Sep 2008 | B2 |
7431733 | Knight | Oct 2008 | B2 |
7435257 | Lashinski et al. | Oct 2008 | B2 |
7445632 | McGuckin, Jr. et al. | Nov 2008 | B2 |
7455689 | Johnson | Nov 2008 | B2 |
7470284 | Lambrecht et al. | Dec 2008 | B2 |
7470285 | Nugent et al. | Dec 2008 | B2 |
7473275 | Marquez | Jan 2009 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7500989 | Solem et al. | Mar 2009 | B2 |
7503929 | Johnson et al. | Mar 2009 | B2 |
7503930 | Sharkawy et al. | Mar 2009 | B2 |
7510572 | Gabbay | Mar 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7513909 | Lane et al. | Apr 2009 | B2 |
7534261 | Friedman | May 2009 | B2 |
7556646 | Yang et al. | Jul 2009 | B2 |
7578828 | Gittings et al. | Aug 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7591848 | Allen | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7625403 | Krivoruchko | Dec 2009 | B2 |
7632296 | Malewicz | Dec 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7780726 | Seguin | Aug 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7846204 | Letac et al. | Dec 2010 | B2 |
7896915 | Guyenot et al. | Mar 2011 | B2 |
7914575 | Guyenot et al. | Mar 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
8002825 | Letac et al. | Aug 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8057540 | Letac et al. | Nov 2011 | B2 |
8092518 | Schreck | Jan 2012 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8403983 | Quadri | Mar 2013 | B2 |
8603159 | Seguin et al. | Dec 2013 | B2 |
8628571 | Hacohen et al. | Jan 2014 | B1 |
9351831 | Braido et al. | May 2016 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20020177894 | Acosta et al. | Nov 2002 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030028213 | Thill et al. | Feb 2003 | A1 |
20030042186 | Boyle | Mar 2003 | A1 |
20030114913 | Spenser | Jun 2003 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040044400 | Cheng et al. | Mar 2004 | A1 |
20040093063 | Wright et al. | May 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040254594 | Alfaro | Dec 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050070794 | Deal et al. | Mar 2005 | A1 |
20050070957 | Das | Mar 2005 | A1 |
20050113910 | Paniagua et al. | May 2005 | A1 |
20050137681 | Shoemaker et al. | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050137702 | Haug et al. | Jun 2005 | A1 |
20050182483 | Osborne et al. | Aug 2005 | A1 |
20050267523 | Devellian et al. | Dec 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20050288706 | Widomski et al. | Dec 2005 | A1 |
20060004442 | Spenser et al. | Jan 2006 | A1 |
20060122692 | Gilad et al. | Jun 2006 | A1 |
20060161248 | Case et al. | Jul 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen | Nov 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20070060998 | Butterwick et al. | Mar 2007 | A1 |
20070061002 | Paul et al. | Mar 2007 | A1 |
20070073387 | Forster et al. | Mar 2007 | A1 |
20070118210 | Pinchuk | May 2007 | A1 |
20070179600 | Vardi | Aug 2007 | A1 |
20070198097 | Zegdi | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070239265 | Birdsall | Oct 2007 | A1 |
20070239269 | Dolan et al. | Oct 2007 | A1 |
20070244546 | Francis | Oct 2007 | A1 |
20070282436 | Pinchuk | Dec 2007 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071362 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071368 | Tuval et al. | Mar 2008 | A1 |
20080077234 | Styrc | Mar 2008 | A1 |
20080125859 | Salahieh et al. | May 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080161909 | Kheradvar et al. | Jul 2008 | A1 |
20080177381 | Navia et al. | Jul 2008 | A1 |
20080195199 | Kheradvar et al. | Aug 2008 | A1 |
20080208327 | Rowe | Aug 2008 | A1 |
20080228263 | Ryan | Sep 2008 | A1 |
20080234814 | Salahieh et al. | Sep 2008 | A1 |
20080255660 | Guyenot et al. | Oct 2008 | A1 |
20080269878 | Iobbi | Oct 2008 | A1 |
20080275550 | Kheradvar et al. | Nov 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090164006 | Seguin et al. | Jun 2009 | A1 |
20090171432 | Von Segesser et al. | Jul 2009 | A1 |
20090171447 | Von Segesser et al. | Jul 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100168839 | Braido et al. | Jul 2010 | A1 |
20110040374 | Goetz et al. | Feb 2011 | A1 |
20110098802 | Braido | Apr 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110224780 | Tabor et al. | Sep 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120116496 | Chuter et al. | May 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120172982 | Stacchino et al. | Jul 2012 | A1 |
20120303116 | Gorman et al. | Nov 2012 | A1 |
20130190861 | Chau et al. | Jul 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20180263765 | Flaction | Sep 2018 | A1 |
Number | Date | Country |
---|---|---|
20063288896 | Jun 2007 | AU |
2007294199 | Mar 2008 | AU |
2009200985 | Apr 2009 | AU |
2634358 | Jun 2007 | CA |
2657839 | Mar 2008 | CA |
2659690 | Mar 2008 | CA |
20003874 | May 2000 | DE |
19857887 | Jul 2000 | DE |
102005003632 | Aug 2006 | DE |
202007005491 | Jun 2007 | DE |
0592410 | Apr 1994 | EP |
0657147 | Jun 1995 | EP |
0696447 | Feb 1996 | EP |
0943302 | Sep 1999 | EP |
1093771 | Apr 2001 | EP |
12511797 | Oct 2002 | EP |
1262201 | Dec 2002 | EP |
1264582 | Dec 2002 | EP |
1267753 | Jan 2003 | EP |
1598031 | Nov 2005 | EP |
1968491 | Sep 2008 | EP |
2033593 | Mar 2009 | EP |
2047824 | Apr 2009 | EP |
2059192 | May 2009 | EP |
2074964 | Jul 2009 | EP |
2815844 | May 2002 | FR |
2874812 | Mar 2006 | FR |
9117720 | Nov 1991 | WO |
982907 | Sep 1998 | WO |
0028922 | May 2000 | WO |
0047139 | Aug 2000 | WO |
0053122 | Sep 2000 | WO |
0149213 | Jul 2001 | WO |
0156505 | Aug 2001 | WO |
0162189 | Aug 2001 | WO |
0176510 | Oct 2001 | WO |
02067782 | Sep 2002 | WO |
02076349 | Oct 2002 | WO |
03003949 | Jan 2003 | WO |
03047468 | Jun 2003 | WO |
03063729 | Aug 2003 | WO |
2005070343 | Aug 2005 | WO |
2005102015 | Nov 2005 | WO |
2006058163 | Jun 2006 | WO |
2006068944 | Jun 2006 | WO |
2006083763 | Aug 2006 | WO |
2006086135 | Aug 2006 | WO |
2006086736 | Aug 2006 | WO |
2006127765 | Nov 2006 | WO |
2007009117 | Jan 2007 | WO |
2007071436 | Jun 2007 | WO |
2008028569 | Mar 2008 | WO |
2008040555 | Apr 2008 | WO |
2008070442 | Jun 2008 | WO |
2009024859 | Feb 2009 | WO |
2009053497 | Apr 2009 | WO |
2009091509 | Jul 2009 | WO |
2010008548 | Jan 2010 | WO |
2010045238 | Apr 2010 | WO |
2010045297 | Apr 2010 | WO |
2010049160 | May 2010 | WO |
2010083558 | Jul 2010 | WO |
2011051043 | May 2011 | WO |
2011057087 | May 2011 | WO |
2012048035 | Apr 2012 | WO |
2013033791 | Mar 2013 | WO |
2013086132 | Jun 2013 | WO |
2013134214 | Sep 2013 | WO |
2014072439 | May 2014 | WO |
2014121042 | Aug 2014 | WO |
2014158710 | Oct 2014 | WO |
2014163706 | Oct 2014 | WO |
Entry |
---|
Australian Examination Report dated Mar. 4, 2010 for Australian Application No. 2009200985. |
Dewey , Todd M. , “Transapical Aortic Valve Implantation : An Animal Feasibility Study” , The Annals of Thoracic Surgery , vol. 82 , pp. 110-116. 2006. |
European Examination Report dated Aug. 11, 2009 for European Application No. 07818037 . 9 , filed Aug. 23 , 2007. |
European Search Report dated May 29 , 2009 for European Application No. 09154935.2 , filed Aug. 23, 2007. |
Examination Report dated Feb. 6, 2009 for European Application No. 06841127.1, filed Dec. 22, 2006. |
International Preliminary Report on Patentability dated Dec. 6, 2011 for Application No. PCT/EP201 0/057798, filed Jun. 3, 2010. |
International Preliminary Report on Patentability dated Feb. 24, 2010 for PCT/IB2008/002180, filed Aug. 21, 2008. |
International Preliminary Report on Patentability dated Jun. 24, 2008 for PCT/EP2006/012455, filed Dec. 22, 2006. |
International Preliminary Report on Patentability dated Mar. 10, 2009 for PCT/EP2007/007413, filed Aug. 23, 2007. |
International Preliminary Report on Patentability dated Mar. 26, 2013 for PCT/EP2011/066677, filed D Sep. 26, 2011. |
International Preliminary Report on Patentability dated May 8, 2012 and Written Opinion for Application No. PCT/EP201 0/063306, filed Sep. 10, 2010. |
International Preliminary Report on Patentability, dated Sep. 15, 2015, for International Application No. PCT/EP2013/000893. |
International Search Report dated Apr. 15, 2009 and Written Opinion for Application No. PCT/IB2008/002180, filed Aug. 21, 2008. |
International Search Report dated Feb. 17, 2012 for Application No. PCT/EP2011/066677, filed Sep. 26, 2011. |
International Search Report dated Jan. 28, 2008 for Application No. PCT/EP2007/007413, filed Aug. 23, 2007. |
International Search Report dated Mar. 25, 2009 and Written Opinion for Application No. PCT/EP2008/064558, filed Oct. 27, 2008. |
International Search Report dated Nov. 17, 2010 for Application No. PCT/EP2010/063306, filed Sep. 10, 2010. |
International Search Report dated Dec. 9, 2010 for Application No. PCT/EP2010/057798, filed Jun. 3, 2010. |
International Search Report dated Sep. 27, 2007 for PCT/EP2006/012455, filed Dec. 22, 2006. |
Ma, Liang et al., “Double-crowned valved stents for off-pump mitral valve replacement” European Journal of Cardia-Thoracic Surgery, vol. 28, pp. 194-199, 2005. |
Mack, M. J., “Minimally invasive cardiac surgery”, Surg. Endosc, vol. 20, pp. S488-S492, 2006. |
International Search Report dated Sep. 4, 2014 for PCT/EP2014/055044, filed Mar. 13, 2014. |
Pawelec-Wojtalk, et al., “Closure of Left Ventricle Perforation with the Use of Muscular VSD Occluder”, European Journal of Cardio-thoracic Surgery, vol. 27, pp. 714-716, 2005. |
Walther, Thomas et al., “Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”, European Journal of Cardio-thoracic Surgery, vol. 29, pp. 703-708, 2006. |
Weerasinghe, Arjuna et al., “First Redo Heart Valve Replacement: A 10-Year Analysis”, Journal of the American Heart Association, vol. 99, pp. 655-658, 1999. |
Atkins, Cary W. et al., Risk of Reoperative Valve Replacement for Failed Mitral and Aortic Bioprostheses, The Annals of Thoracic Surgery, vol. 65; pp. 1545-1552, 1998. |
International Search Report dated Apr. 17, 2014 for PCT/EP2013/073318, filed Nov. 8, 2013. |
European Search Report dated Jan. 30, 2020 for European Application No. 19203816.4-1113. |
Number | Date | Country | |
---|---|---|---|
20190201193 A1 | Jul 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14777503 | US | |
Child | 16295394 | US | |
Parent | 13839357 | Mar 2013 | US |
Child | 14777503 | US |